<DOC>
	<DOC>NCT01438489</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of MEDI-546 compared to placebo in subjects with chronic, moderately-to-severely active systemic lupus erythematosus (SLE) with an inadequate response to standard of care treatment for SLE.</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of 2 intravenous (IV) treatment regimens in adult participants with chronic, moderately-to-severely active SLE with an inadequate response to SOC SLE. The investigational product (anifrolumab or placebo) will be administered as a fixed dose every 4 weeks (28 days) for a total of 13 doses.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Fulfills at least 4 of the 11 American College of Rheumatology (ACR) criteria for systemic lupus erythematosus (SLE) including a positive antinuclear antibody (ANA) greater than or equal to 1:80 or elevated antidoublestranded DNA or antiSmith antibody at screening Pediatric or adult SLE with chronic disease activity for greater than or equal to 24 weeks Weight greater than or equal to 40 kg Currently receiving stable dose of oral prednisone (or equivalent) less than or equal to 40 mg/day and/or antimalarials/immunosuppressives Active moderate to severe SLE disease based on SLE disease activity score (SLEDAI) and British Isles Lupus Assessment Group Index (BILAG) and Physicians Global Assessment No evidence of cervical malignancy on Pap smear within 2 years of randomization Female participants must be willing to avoid pregnancy Negative tuberculosis (TB) test or newly positive TB test due to latent TB for which treatment must be initiated at or before randomization. Active severe SLEdriven renal disease or unstable renal disease prior to screening Active severe or unstable neuropsychiatric SLE Clinically significant active infection including ongoing and chronic infections History of human immunodeficiency virus (HIV) Confirmed Positive tests for hepatitis B or positive test for hepatitis C History of severe herpes infection such as herpes encephalitis, ophthalmic herpes, disseminated herpes Live or attenuated vaccine within 4 weeks prior to screening Participants with significant hematologic abnormalities.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MEDI-546</keyword>
	<keyword>Anifrolumab</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
</DOC>